Aclaris Therapeutics Inc., of Malvern, Pa., said it entered a stock purchase agreement with a group of institutional accredited investors for the private placement of just over 1 million shares of common stock at $18.50 each, for expected gross proceeds of $20 million. Net proceeds are expected to be used to fund research and development, including new JAK inhibitor programs for androgenetic alopecia (also known as male or female pattern baldness) and vitiligo, as well as ongoing business development.
Atossa Genetics Inc., of Seattle, said it entered a stock purchase agreement with Aspire Capital Fund LLC, which has committed to purchase up to $10 million of Atossa’s common stock over 30 months, based on prevailing market prices over a period preceding each sale.
Intellipharmaceutics International Inc., of Toronto, said it intends to offer units of its common shares and warrants in an underwritten public offering. Dawson James Securities Inc. is acting as sole bookrunner. No terms have yet been set.
Oncosec Medical Inc., of San Diego, said it closed its at-the-market registered direct offering with a single health care institutional fund for the purchase of 5.5 million shares of its common stock at $1.815, or pre-funded warrants in lieu at $1.805, and warrants to purchase up to an aggregate of 5.5 million shares of common stock at an exercise price of $1.69 each. The gross proceeds of the offering were $10 million.